Luteolin.|491-70-3|(木犀草素; Luteoline; Luteolol; Digitoflavone)-陌孚医药/Medlife

您当前的位置：

Luteolin. (Synonyms: 木犀草素; Luteoline; Luteolol; Digitoflavone)

目录号: PC11620 纯度: ≥98%

CAS No. :491-70-3

商品编号	规格	价格	会员价	是否有货	数量
PC11620-20mg	20mg	¥955.00	请登录
PC11620-10mM (in 1mL DMSO)	10mM (in 1mL DMSO)	¥637.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称

Luteolin.

中文别名

木犀草素;3',4',5,7-四羟基黄酮;檞片素;木樨草素;四羟黄酮;3 ,4 ,5,7-四羟基黄酮;3',4',5,7-Tetrahydroxyflavone 3',4',5,7-四羟基黄酮;Luteolin 木犀草素标准品;WAKO125-05441毛地黄黄酮;布洛芬;木犀草素（标准品）;木犀草素,Luteolin,植物提取物,标准品,对照品;木犀草素Luteolin;木犀草素对照品;木樨草素(P);木樨草素(SH);续随二萜醇;3',4',5,7-四羟黄酮;3',4',5,7-四羟基黄酮,黄色黄素,黄示灵,藤黄菌素;黄色黄素;木犀草素(黄色黄素,黄示灵,毛地黄黄酮,藤黄菌素,3',4',5,7-四羟黄酮);木犀草素(黄色黄素,黄示灵,毛地黄黄酮,藤黄菌素,3',4',5,7-四羟黄酮);木犀草素,3＇,4＇,5,7-四羟基黄酮;木犀草素[橙皮苷半合成],黄色黄素;片素;藤黄菌素,毛地黄黄酮

英文名称

Luteolin

英文别名

2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one;2-(3,4-DIHYDROXYPHENYL)-5,7-DIHYDROXY-4H-1-BENZOPYRAN-4-ONE;2-(3,4-DIHYDROXY-PHENYL)-5,7-DIHYDROXY-CHROMEN-4-ONE;3',4',5,7-TETRAHYDROXYFLAVONE,FLACITRAN,LUTEOLOL;5,7,3',4'-TETRAHYDROXYFLAVONE;FLACITRAN;LUTEOLIN-3',7-O-DIGLUCURONIDE;LUTEOLOL;RARECHEM AB DU K001;2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4h-1-benzopyran-4-on;3’,4’,5,7-tetrahydroxy-flavon;c.i.75590;c.i.naturalyellow2;cyanidenon1470;digitoflavone;luteoline;weldlake;2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-benzopyrone;3',4',5,7-Tetrahydroxyflavone;Luteolin;Luteolin (Luteolol, Digitoflavone, Flacitran, Luteoline );LUTEOLIN(P);LUTEOLIN(P) PrintBack;LUTEOLIN(RG);3',4',5,7-tetrahydroxy-flavone;5,7,3',4'-tetrahydroxyflavon;cyanidenon;Flavopurpol;Salifazide;3′,4′,5,7-Tetrahydroxyflavone;[ "3'", "4'", "5", "7-Tetrahydroxyflavone" ];Jujube Extract;3';Weld Lake;Cyanidenon 1470;Yama kariyasu;C.I. Natural Yellow 2;4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-;7-Tetrahydroxyflavone;KUX1ZNC9J2;2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one;2-(3,4-Dihydroxyphenyl)-5,

Cas No.

491-70-3

分子式

C₁₅H₁₀O₆

分子量

286.24

包装储存

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

生物活性

Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells.

性状

Solid

体外研究(In Vitro)

Luteolin (0-160 μM; 24 hours; NCI-H460 cells) treatment inhibits the viability of NCI-H460 cells in a concentration-dependent manner.
Luteolin (20-80 μM; 24 hours; NCI-H460 cells) treatment causes an accumulation of cells in the S phase.
Luteolin (320-580 μM; 48 hours; NCI-H460 cells) treatment induces apoptosis.
Luteolin (20-80 μM; 24 hours; NCI-H460 cells) treatment increases the protein expression levels of apoptotic regulatory proteins, including the Bax/Bcl-2 ratio, in a concentration-dependent manner, however, only 80 μM Luteolin inhibits the expression of Bad. Luteolin also decreases the expression of Sirt1 in the NCI-H460 cell line in a concentration-dependent manner.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	NCI-H460 cells
Concentration:	0 μM, 20 μM, 40 μM, 80 μM and 160 μM
Incubation Time:	24 hours
Result:	Inhibited the viability of NCI-H460 cells in a concentration-dependent manner.

Cell Cycle Analysis

Cell Line:	NCI-H460 cells
Concentration:	20 μM, 40 μM, 80 μM
Incubation Time:	24 hours
Result:	Induced cell cycle arrest in the S phase.

Apoptosis Analysis

Cell Line:	NCI-H460 cells
Concentration:	320 μM, 440 μM, 580 μM
Incubation Time:	48 hours
Result:	Apoptotic fraction was markedly increased.

Western Blot Analysis

Cell Line:	NCI-H460 cells
Concentration:	20 μM, 40 μM, 80 μM
Incubation Time:	24 hours
Result:	Increased the protein expression levels of apoptotic regulatory proteins and decreased the expression of Sirt1 in the NCI-H460 cell line in a concentration-dependent manner.

体内研究(In Vivo)

Luteolin (10-100?mg/kg; oral gavage; daily; for 12 weeks; adult male Wistar rats) has an antioxidant effect and can also protect against non-alcoholic steatohepatitis through targeting the pro-inflammatory IL-1 and Il-18 pathways in rats with a high carbohydrate/high fat diet.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Wistar rats (200-220?g)
Dosage:	10 mg/kg, 25 mg/kg, 50 mg/kg or 100?mg/kg
Administration:	Oral gavage; daily; for 12 weeks
Result:	Significantly reduced ALT and AST activity and reduced levels of bilirubin, hyaluronic acid and malondialdehyde. Shows an antioxidant activity such as a significant increase in reduced glutathione. IFN-γ, TNF-α, IL-1α and IL-18 levels decreased significantly.

运输条件

Room temperature or refrigerated transportation.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

ClinicalTrial

结构分类

来源

参考文献

[1]. Ma L, et al. Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis. Mol Med Rep. 2015 Sep;12(3):4196-4202. [Information]

[2]. Abu-Elsaad N, et al. Protection against nonalcoholic steatohepatitis through targeting IL-18 and IL-1alpha by luteolin. Pharmacol Rep. 2019 Aug;71(4):688-694. [Information]

[3]. Xiuwen Tang, et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med. 2011 Jun 1;50(11):1599-609. [Information]

溶解度数据

体外研究:

DMSO : ≥ 100 mg/mL (349.36 mM)

* "≥" means soluble, but saturation unknown.

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.4936 mL	17.4679 mL	34.9357 mL
5 mM	0.6987 mL	3.4936 mL	6.9871 mL
10 mM	0.3494 mL	1.7468 mL	3.4936 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (7.27 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH?O 中，得到澄清透明的生理盐水溶液
2.

建议依照次序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (7.27 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

建议依照次序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (7.27 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation